SOPH

SOPHiA GENETICS SA

1 day chart

About SOPH

Sophia Genetics SA is a Switzerland-based company engaged in the software publishing sector. The Company offer a cloud-based Software-as-a-Service platform - the SOPHiA DDM, which is data-driven medicine platform enabling insights from disparate, complex datasets to improve diagnosis, treatment, and drug development. The Company has offices in Switzerland, France and the United Kingdom and operates worldwide.

Buy US stocks in Australia starting with SOPH. Open an account and start investing today!

Market Capitalisation

$283.03M

Price-earnings ratio

Dividend yield

0.00%

Volume

1.54K

High today

$4.45

Low today

$4.40

Open price

$4.40

52-week high

$5.77

52-week low

$1.69

SOPH FAQs

Can I buy SOPH shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?

Yes, the Stake platform allows you to buy SOPH shares and over 8,000 stocks and ETFs across the ASX and Wall St.

How much is one share of SOPHiA GENETICS SA?

One share of SOPHiA GENETICS SA is valued at $4.57.

What is the ticker symbol for SOPHiA GENETICS SA?

The ticker symbol for SOPHiA GENETICS SA is SOPH.

How do I buy SOPH shares in Australia?

To buy SOPH stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:

Sign up in minutes, all you need is some I.D.
Choose Stake Wall St
Deposit directly into your Stake wallet and you're ready to invest in SOPH

What is the 52-week high for SOPHiA GENETICS SA stock?

The SOPHiA GENETICS SA 52-week high stock price is $5.77.

What is the 52-week low for SOPHiA GENETICS SA stock?

The SOPHiA GENETICS SA 52-week low stock price is $1.69.

What is the market capitalisation of SOPHiA GENETICS SA SOPH?

As of 30/05/2023 SOPHiA GENETICS SA has a market cap of $283M.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.